HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pieter Sonneveld Selected Research

Bortezomib (Velcade)

1/2022Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
10/2021Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
1/2021Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
1/2021Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
1/2021Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
1/2021Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
1/2021Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
1/2021Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
1/2021Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
12/2020Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pieter Sonneveld Research Topics

Disease

175Multiple Myeloma
02/2022 - 03/2003
25Neoplasms (Cancer)
05/2022 - 01/2005
16Disease Progression
10/2022 - 06/2005
13Peripheral Nervous System Diseases (PNS Diseases)
01/2018 - 01/2006
10Thrombocytopenia (Thrombopenia)
02/2022 - 01/2006
10Neutropenia
02/2022 - 10/2008
8Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2011 - 08/2003
7Residual Neoplasm
02/2022 - 03/2017
7Infections
01/2021 - 05/2013
7Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2008 - 01/2003
5Pain (Aches)
01/2021 - 04/2008
5Amyloidosis
10/2020 - 03/2004
4Pneumonia (Pneumonitis)
02/2022 - 10/2013
4Chromosome Aberrations (Chromosome Abnormalities)
01/2022 - 01/2012
4Anemia
11/2018 - 10/2015
4Waldenstrom Macroglobulinemia (Macroglobulinemia)
01/2017 - 07/2007
4BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
08/2013 - 03/2008
4Renal Insufficiency (Renal Failure)
06/2013 - 12/2008
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
02/2022 - 04/2004
3Testicular Neoplasms (Testicular Cancer)
01/2022 - 10/2010
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2021 - 08/2005
3Immunoglobulin Light-chain Amyloidosis
10/2020 - 01/2018
3Fatigue
10/2018 - 10/2013
2COVID-19
02/2022 - 01/2020
2Bone Diseases (Bone Disease)
01/2022 - 10/2015
2Lymphopenia (Lymphocytopenia)
10/2021 - 11/2018
2Hypertension (High Blood Pressure)
10/2021 - 07/2010
2Lymphoma (Lymphomas)
01/2021 - 07/2007
2Inflammation (Inflammations)
01/2021 - 03/2011
2Painful Neuropathy
01/2018 - 01/2015
2Neuralgia (Stump Neuralgia)
01/2018 - 01/2015
2Cardiovascular Diseases (Cardiovascular Disease)
01/2018 - 01/2017
2Thrombosis (Thrombus)
10/2016 - 07/2010
2Polyneuropathies (Polyneuropathy)
01/2015 - 01/2010
2Hematologic Neoplasms (Hematological Malignancy)
01/2015 - 10/2010
2Thromboembolism
06/2011 - 04/2008
2B-Cell Lymphoma (Lymphoma, B Cell)
06/2011 - 06/2008
2Venous Thrombosis (Deep-Vein Thrombosis)
01/2011 - 10/2008
2Refractory Anemia
04/2010 - 09/2009
2Pulmonary Embolism
12/2008 - 10/2008
2Venous Thromboembolism
12/2008 - 07/2008
2Breast Neoplasms (Breast Cancer)
05/2007 - 12/2002

Drug/Important Bio-Agent (IBA)

80Bortezomib (Velcade)FDA Link
01/2022 - 06/2005
62Dexamethasone (Maxidex)FDA LinkGeneric
02/2022 - 03/2003
41Lenalidomide (CC 5013)FDA Link
02/2022 - 04/2008
34Thalidomide (Thalomid)FDA Link
10/2021 - 01/2008
19Proteasome InhibitorsIBA
02/2022 - 01/2006
19Pharmaceutical PreparationsIBA
01/2022 - 07/2004
18daratumumabIBA
10/2022 - 01/2016
17Melphalan (Alkeran)FDA LinkGeneric
10/2020 - 03/2003
12pomalidomideIBA
02/2022 - 10/2013
12Monoclonal AntibodiesIBA
01/2022 - 06/2008
11Proteins (Proteins, Gene)FDA Link
11/2020 - 12/2002
11Prednisone (Sone)FDA LinkGeneric
06/2020 - 01/2003
9Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 01/2003
8Immunomodulating AgentsIBA
01/2022 - 01/2010
8Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2021 - 01/2003
7carfilzomibIBA
01/2021 - 07/2014
7Vincristine (Oncovin)FDA LinkGeneric
05/2015 - 01/2003
7Cytarabine (Cytosar-U)FDA LinkGeneric
08/2013 - 04/2004
6melflufenIBA
02/2022 - 04/2020
6Proteasome Endopeptidase Complex (Proteasome)IBA
01/2017 - 06/2007
6liposomal doxorubicin (Doxil)FDA Link
07/2016 - 09/2007
5L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2021 - 05/2005
51-dodecylpyridoxal (PLD)IBA
07/2016 - 09/2007
5Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2012 - 08/2003
4Biological ProductsIBA
11/2020 - 06/2014
4AnthracyclinesIBA
01/2018 - 07/2004
4DNA (Deoxyribonucleic Acid)IBA
04/2017 - 04/2007
4Imatinib Mesylate (Gleevec)FDA Link
08/2013 - 03/2008
4EnzymesIBA
11/2010 - 10/2006
4Member 1 Subfamily B ATP Binding Cassette TransporterIBA
11/2010 - 12/2002
3AntigensIBA
01/2022 - 10/2010
3Chimeric Antigen ReceptorsIBA
02/2021 - 12/2019
3Alkylating AgentsIBA
09/2020 - 02/2012
3Daunorubicin (Cerubidine)FDA LinkGeneric
09/2009 - 07/2004
3thiamine triphosphorate (TTP)IBA
04/2008 - 03/2003
3major vault proteinIBA
05/2007 - 12/2002
3Green Fluorescent ProteinsIBA
02/2006 - 11/2003
2ATP-Binding Cassette Transporters (ABC Transporters)IBA
01/2022 - 12/2002
2Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2018
2ixazomibIBA
01/2021 - 12/2020
2CytokinesIBA
01/2021 - 04/2016
2Complement System Proteins (Complement)IBA
12/2020 - 06/2008
2AminopeptidasesIBA
09/2020 - 10/2010
2Peptides (Polypeptides)IBA
09/2020 - 04/2020
2Immunoglobulin G (IgG)IBA
11/2018 - 06/2014
2Adrenal Cortex Hormones (Corticosteroids)IBA
01/2018 - 05/2013
2Rituximab (Mabthera)FDA Link
01/2017 - 11/2013
2CreatinineIBA
01/2016 - 12/2008
2Amyloid (Amyloid Fibrils)IBA
05/2015 - 03/2004
2Factor VIII (Coagulation Factor VIII)IBA
07/2010 - 07/2007
2valspodar (PSC 833)IBA
02/2006 - 10/2005

Therapy/Procedure

79Therapeutics
10/2022 - 03/2003
24Stem Cell Transplantation
01/2021 - 05/2003
17Drug Therapy (Chemotherapy)
06/2020 - 01/2003
5Transplantation
01/2021 - 09/2005
3Induction Chemotherapy
04/2010 - 08/2003
2Remission Induction
08/2020 - 03/2003
2Drug Tapering
02/2012 - 04/2008